{"prompt": "['Appendix 1: Investigator Signature Page', 'Bridging Care to HCV Treatment Among Opioid Dependent Patients on Buprenorphine/naloxone', 'Maintenance Therapy: A Pilot Study of Treating HCV with Epclusa at a Psychiatrist-staffed Outpatient', 'Addiction Clinic Clinic', 'September 13, 2017 V7.0', 'Investigator Statement', 'I have read the protocol, including all appendices, and I agree that it contains all necessary details or my', 'staff to conduct this study as described. I will conduct his study as outlined herein and will make a', 'reasonable effort to complete the study within the time designated.', 'I', 'will provide all study personnel under my supervision copies of the protocol and access to all study-', 'related information. I will discuss this material with them to ensure that they are fully informed about', 'the drugs and the study.', 'I affirm that the protocol, GCP guidelines and applicable regulatory requirements will be followed.', 'I will not initiate any study activities until the IRB/IEC and other required regulatory approvals are', 'obtained.', 'Principal Investigator Name (Printed)', 'Signature', 'Date', 'CRI 15-05 Protocol 13SEP2017', 'Page 46']['Appendix 2:', 'Study Procedures Table', 'Screening', 'Baseline', 'Biweekly Visits on', 'Unscheduled', 'EOT or early', 'Post-Treatment', 'Treatmenth', 'Visit', 'termination', 'weeks 4 and 12', 'Clinical Assessments:', 'Informed Consent', 'X', 'Eligibility Review', 'X', 'X', 'Medical History', 'X', 'Adverse Events', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant Medication Review', 'X', 'X', 'X', 'X', 'X', 'Pregnancy Prevention Counseling for', 'X', 'X', 'X', 'X', 'X', 'WOCBP', 'Health Related QOL Surveysb', 'X (post treatment', 'X', 'X (week 4 only)', 'X', 'week 12 only)', 'Drug Dispensing', 'X', 'X\u00b9', 'Instruct the subject on the packaging,', 'storage and administration of study', 'X', 'drug', 'Pill count', 'X', 'X', 'X', 'Download MEMSCapTM', 'adherence data', 'X', 'X', 'X', 'Laboratory Assessments:9', 'Hepatic Function Tests', 'X', 'X\u00b0', 'CBC with Platelet Count\u00b0', 'BMP with eGFR', 'X', 'HgbA1C', 'X', 'HCV RNAd', 'X', 'Xd', 'X', 'HCV genotype if not documented in', 'X', 'medical record', 'FibroSureR', 'X', 'Hepatitis B surface antibody, core', 'X', 'antibody, surface antigen', 'Hepatitis B quantitative DNA PCR test', 'X', 'Xd', 'Urine drug screen', 'X', 'X', 'X', 'X', 'Urine screen for buprenorphine', 'X', 'X', 'X', 'X', 'CRI 15-05 Protocol 13SEP2017', 'Page 47']['Screening', 'Baseline', 'Biweekly Visits on', 'Unscheduled', 'EOT or early', 'Post-Treatment', 'Treatmenth', 'Visit', 'termination', 'weeks 4 and 12', 'Serum Pregnancy Test for WOCBP', 'X', 'Urine Pregnancy Test for WOCBP', 'X (post treatment', 'X', 'X', 'week 4 only)', 'Internal Medicine Mentorship and Assessments:', 'Psychiatrist Sub-Investigator', 'X', 'X', 'X', 'X', 'X', 'X', 'Mentorship e', 'Psychiatrist Sub-Investigator', 'X', 'X', 'Questionnaire', 'f', 'a', 'Select', 'Medical History to include: risk factor(S) for HCV, estimated duration of HCV, prior assessments of fibrosis, HCV genotype if known, prior', 'HCV treatment, comorbid liver diseases', 'b', 'FACIT-F, PROMIS ED -Depression SF8a, SF36', 'c', 'ALT, AST, and platelet count will be used to calculate FIB-4 Index', 'd', 'HCV RNA, HBV DNA and HFT to be assessed at week 4 on treatment but not at other biweekly on treatment visits unless clinically indicated', 'e Detailed teaching session prior to screening', 'f Administered before and at the completion of the training session and after 4 months of prescribing of HCV therapy to study participants.', 'g Additional safety laboratory assessments may be assessed per the clinical judgement of the Sponsor-Investigator or Sub-Investigator.', 'h', 'While the goal is for all visits to be within +/-3 days of the target visit date, study visits will be accepted outside of the window as required by the', 'patient and the operational flow of the clinic.', 'I Study drug will be dispensed at the week 4 and week 8 study visits, and as needed at other visits for emergency resupply.', 'CRI 15-05 Protocol 13SEP2017', 'Page 48']\n\n###\n\n", "completion": "END"}